Conclusion. Accumulation of M3G and M6G is due to the substantially lowered clearance by residual Background. Conjugation with glucuronic acid represents the major route of biotransformation of morphine. renal function and peritoneal dialysis. In view of the accumulation of potential active metabolites, subThe glucuronides morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) are eliminated via the sequent investigations have to assess the frequency of side-effects in patients on CAPD. kidneys. Therefore, chronic renal failure should affect the disposition of M3G and M6G. Numerous patients undergoing long-term continuous ambulatory periton-Key words: morphine; morphine glucuronides; peritoneal dialysis (CAPD) require pain treatment with eal dialysis; pharmacokinetics; renal failure morphine. There are only limited data available about the disposition of morphine and its active metabolites M6G and M3G in patients on CAPD. We therefore investigated the pharmacokinetics of morphine and its Introduction metabolites in CAPD patients. Methods. This was a single intravenous dose pharm-Morphine remains the analgesic drug of choice for acokinetic study in 10 CAPD patients (1 female, 9 treatment of severe acute and chronic pain syndromes. male, age 31-69 years). Morphine-hydrochloride (Mo) In humans morphine is almost completely metabolized (10 mg) was administered intravenously. Serum, urine, by the liver. The principal route of biotransformation and dialysate samples were collected during 24 h. is the glucuronidation of morphine by glucuronyl GC-MS-MS and HPLC-MS methods were used transferase. In healthy volunteers approximately to quantify respectively morphine and morphine 80-90% of an intravenously administered dose of glucuronides.
were stored at −20°C for analysis. Venous blood samples There are only limited data on the pharmacokinetics (6 ml ) were taken from a cannula in the opposite limb of morphine available in continuous ambulatory periimmediately before administration of morphine and 5, 30, toneal dialysis patients. Osborne et al. [2] studied 60, 120 min and 4, 8, 12, 23 and 24 h after the end of morphine disposition in CAPD patients immediately morphine infusion. After centrifugation serum samples were after placement of peritoneal catheter before a stable stored at −20°C until analysis. In patients with residual CAPD regime was established. Furthermore, urine and diuresis, urine was collected over 24 h after the infusion. dialysis solution were not sampled in that study. The After quantifying total urine volume aliquots (20 ml ) were aim of our study was therefore to obtain more detailed stored at −20°C. data about disposition and excretion of morphine and morphine glucuronides in CAPD patients.
Analytical methods
Analysis of morphine was performed by gas chromato-
Subjects and methods
graphy/tandem mass spectrometry (GC-MS-MS), analogous to an assay technique described for dihydrocodeine [9] . Morphine glucuronides were quantified simultaneously by
Patients
high-pressure liquid chromatography with electrochemical detection (HPLC-MS ) in accordance with an assay techAfter obtaining Ethics Committee approval and written niques described previously [10] . informed consent, 10 CAPD patients in the dialysis unit of the Robert-Bosch-Hospital Stuttgart (1 female, 9 male, age 31-69 years, mean 55.5±10 years) were studied. The under-Pharmacokinetic parameters lying renal disease were chronic glomerulonephritis in three, diabetic nephropathy in six, and nephrosclerosis in one case. Pharmacokinetic parameters of morphine and its glucuronides in serum were calculated using Topfit 2.0B PharmacoFour of the patients were anuric and six had residual diuresis ranging from 400 to 2000 ml/24 h. Duration of peritoneal dynamic and Pharmacokinetic Data Analysis System for PC (Gustav Fischer Verlag, Stuttgart, Germany). dialysis (PD) ranged from 3 to 60 months (mean 28.5±18 months). Patients who had had peritonitis within the previous
The area under the concentration-time curve (AUC ) was calculated according to the linear trapezoidal rule. 2 months were excluded. The patients' adequacy of CAPD treatment calculated as weekly Kt/V (weekly clearance of Concentrations of morphine, M3G or M6G were calculated using the amounts of morphine, M3G and M6G excreted in times the duration of CAPD treatment divided by the volume of distribution of urea in the body) and creatinine clearance the urine (E u ) and dialysate ( E CAPD ). Renal clearance (CL R ) and PD clearance (CL CAPD ) were determined as E u and E CAPD were available with not more than 7 months (mean 4.7±1.8 months) interval between Kt/V-test and study. No patient of morphine, M3G, and M6G divided by the AUC of the corresponding compound.Total serum clearance of morphine was receiving concurrent treatment with morphine or other narcotics. Details on patients are summarized in Table 1 .
(CL sys ) was determined using the formula dose/AUC. The results are given as mean±SD.
Experimental protocol

Results
All patients received a single dose of morphine hydrochloride (10 mg, 26.6 mmol ) in 100 ml NaCl 0.9% infused over 10 min, Generally the drug was well tolerated. One patient starting at 8 a.m. after the fill following the drain of the complained about nausea and vomiting 30 min after overnight dialysis solution. Thereafter four exchanges of the the infusion of morphine which resolved after intraven-PD solution were made at 5,10,15 and 24 h after the end of ous injection of 10 mg metoclopramide hydrochloride.
the infusion. The volumes were measured in conjunction with each exchange and aliquots of dialysis fluid (20 ml ) Two patients complained about temporary dizziness. None of the remaining seven patients had any adverse M3G (3.9±2.2 ml/min), and M6G (3.6±2.2 ml/min) was also less than 1% of CL sys of morphine. CL R of effect during or after the infusion.
Whereas the serum concentration-time curves of M3G and M6G was correlated to creatinine clearance (M3G. ( Figures 5 and 6) . In all patients, most of the morphine serum clearance took place via routes other than PD after the end of infusion (Figure 1) . Dialysate concentration-time curves of morphine, M3G, and M6G show or kidneys, i.e. by non-renal, non-CAPD clearance.
In view of the accumulation of morphine glucurona similar behaviour, with a decline of morphine and accumulation of M3G and M6G (Figure 2 ). Only ides, clearance of morphine is due to its metabolism to M3G and M6G, while the accumulation of M3G 11.9±4.0% of the infused morphine was excreted in dialysate as morphine, M3G, or M6G during 24 h and M6G is readily explained by the substantially lowered clearance by residual renal function and (Figure 3 ). In patients with residual renal function an additional amount of 12.0±7.9% was excreted in the peritoneal dialysis.
Based on these results, repeated i.v. administration urine as morphine, M3G, and M6G (Figure 3) .
The pharmacokinetic parameters of morphine, of morphine in a clinical setting of an acute pain syndrome in PD patients is expected to result in an M3G, and M6G are summarized in Table 2 Figure 4 . CL CAPD of morphine (4.1±1.4 ml/min), of 10 mg morphine-HCl were fitted to a threecompartment model ( Topfit 2.0). Using these obtained M3G (3.2±0.7 ml/min), and M6G (3.0±0.8 ml/min) accounted for less than 1% of CL sys of morphine parameters an extrapolation of serum concentrationtime curves of morphine, M3G, and M6G for a 3-day (1246.2±239.7 ml/min). In those patients with residual renal function, CL R of morphine (3.0±2.46 ml/min), treatment period with a dosing regime of 5 mg morphine HCl given i.v. four times a day was carried respectively. Both assay techniques are well established out; this is half the dose given in patients without renal and very sensitive. GC-MS-MS detecting limit of morimpairment in the ususal interval. While extrapolation phine is 50 fmol/ml, while HPLC-MS detecting limits data show no accumulation of morphine after a 3-day for M3G and M6G are 2.5 pmol/ml and 0.5 pmol/ml, treatment period, M3G and M6G serum levels increase respectively. more than five times the level seen after single i.v. Our data show that after single-dose i.v. administraadministration of morphine ( Figure 7) . tion of 10 mg morphine HCl, serum concentrations of morphine decrease over the following 24 h, while morphine metabolites show substantial accumulation.
Discussion
Compared with published data about disposition of morphine metabolites after i.v. administration, AUC ratios of M3G5Mo and M6G5Mo is 5.5 and 13.5 In the present study GC-MS-MS and HPLC-MS times higher than in patients with normal kidney methods were used to quantify serum and dialysate levels of morphine and morphine-glucuronides, function [11] . While accumulation of morphine metabolites is due to its substantially lowered clearance to cautious dosing of morphine in patients with endstage renal disease, which is recommended to be 50% by residual renal function and peritoneal dialysis, elimination of morphine mainly takes place by meta-of the normal dose at the usual interval. On the other hand, as shown in our model, accumulation of morphine bolism to morphine glucuronides.
In view of the accumulation of morphine metabolites glucuronides is expected to occur even under repeated administration of a reduced morphine dose. We thereit has been suggested that side-effects of morphine in patients with renal failure are related to accumulation fore have to consider possible additional factors affecting the occurrence of adverse events in patients of the active morphine metabolite M6G [5] . The analgesic properties of M6G were recognized in the with ESRD after repeated administration of morphine.
It can be suspected that although serum levels early 1970s [7] and more recent studies in animals and humans suggest that M6G might have an analgesic of M6G in patients with renal failure are very high, under normal conditions M6G cannot pass across the potency many times that of morphine, depending on the route of administration [12, 13] . blood brain brarrier (BBB) in amounts that produce analgesic effects or side-effects. Recent studies demonAlthough our, and previously published pharmacokinetic data, indicate an extreme accumulation of M6G strated that the transport of M6G across the BBB depends on an active transport mechanism, mediated after single i.v. administration of morphine-which is expected to further increase under continuous treat-by the 170-kD P-glycoprotein [14] . P-glycoprotein is an ATP-dependent carrier system that acts as an active ment with morphine-none of the patients in the present study experienced respiratory depression or efflux pump to transport chemicals or metabolites from within the endothelial cell back to the blood compartprolonged narcotic effect, and the number of published cases of serious adverse events in patients with renal ment. Thus, P-glycoprotein poses a serious obstacle for the delivery of some drugs to CNS. impairment is small. In the latter case this may be due
In patients with renal impairment, occurrence of adverse events might depend on co-medication as well.
In a recent study of Lö tsch et al.
[18] M6G failed to demonstrate any analgesic effect after short-term i.v. administration in healthy volunteers. It can therefore be suspected that after single administration of morphine, brain concentrations of M6G are not high enough to produce an analgesic effect. Severe adverse events during morphine treatment in patients with renal impairment are almost always reported after repeated opiate administration.
In conclusion, our data show that CAPD patients accumulate morphine glucuronides after single i.v. administration of morphine, while systemic clearance of morphine is in the range observed in patients with normal kidney function. The accumulation of morphine glucuronides in serum is due to the substantially lowered clearance by CAPD or residual renal function. In view of the accumulation of an active metabolite, subsequent investigations have to assess the frequency of side-effects in patients on CAPD and the pharmacodynamic role of morphine metabolites in these patients. Better understanding of the transport mechanism of M6G on the BBB could help to identify patient at higher risk of developing opiate toxicity.
